Viking Therapeutics recently initiated a Phase 1 single ascending dose trial of VK3019, a dual amylin and calcitonin receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results